Application of High-Throughput Next-Generation Sequencing for HLA Typing on Buccal Extracted DNA: Results from over 10,000 Donor Recruitment Samples. by Yin, Yuxin et al.
UCLA
UCLA Previously Published Works
Title
Application of High-Throughput Next-Generation Sequencing for HLA Typing on Buccal 
Extracted DNA: Results from over 10,000 Donor Recruitment Samples.
Permalink
https://escholarship.org/uc/item/27q5t4bs
Journal
PloS one, 11(10)
ISSN
1932-6203
Authors
Yin, Yuxin
Lan, James H
Nguyen, David
et al.
Publication Date
2016
DOI
10.1371/journal.pone.0165810
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
RESEARCH ARTICLE
Application of High-Throughput Next-
Generation Sequencing for HLA Typing on
Buccal Extracted DNA: Results from over
10,000 Donor Recruitment Samples
Yuxin Yin1☯, James H. Lan2☯, David Nguyen1, Nicole Valenzuela1, Ping Takemura1, Yung-
Tsi Bolon3, Brianna Springer3, Katsuyuki Saito4, Ying Zheng1, Tim Hague5,
Agnes Pasztor5, Gyorgy Horvath5, Krisztina Rigo5, Elaine F. Reed1, Qiuheng Zhang1*
1 UCLA Immunogenetics Center, Department of Pathology & Laboratory Medicine, Los Angeles, CA, United
States of America, 2 University of British Columbia Clinician Investigator Program, Vancouver, BC, Canada,
3 National Marrow Donor Program, Minneapolis, MN, United States of America, 4 One Lambda, Thermo
Fisher Scientific, Canoga Park, CA, United States of America, 5 Omixon LTD, Budapest, Hungary
☯ These authors contributed equally to this work.
* jqzhang@mednet.ucla.edu
Abstract
Background
Unambiguous HLA typing is important in hematopoietic stem cell transplantation (HSCT),
HLA disease association studies, and solid organ transplantation. However, current molec-
ular typing methods only interrogate the antigen recognition site (ARS) of HLA genes,
resulting in many cis-trans ambiguities that require additional typing methods to resolve.
Here we report high-resolution HLA typing of 10,063 National Marrow Donor Program
(NMDP) registry donors using long-range PCR by next generation sequencing (NGS)
approach on buccal swab DNA.
Methods
Multiplex long-range PCR primers amplified the full-length of HLA class I genes (A, B, C)
from promotor to 3’ UTR. Class II genes (DRB1, DQB1) were amplified from exon 2
through part of exon 4. PCR amplicons were pooled and sheared using Covaris fragmen-
tation. Library preparation was performed using the Illumina TruSeq Nano kit on the Beck-
man FX automated platform. Each sample was tagged with a unique barcode, followed
by 2×250 bp paired-end sequencing on the Illumina MiSeq. HLA typing was assigned
using Omixon Twin software that combines two independent computational algorithms to
ensure high confidence in allele calling. Consensus sequence and typing results were
reported in Histoimmunogenetics Markup Language (HML) format. All homozygous
alleles were confirmed by Luminex SSO typing and exon novelties were confirmed by
Sanger sequencing.
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Results
Using this automated workflow, over 10,063 NMDP registry donors were successfully
typed under high-resolution by NGS. Despite known challenges of nucleic acid degradation
and low DNA concentration commonly associated with buccal-based specimens, 97.8% of
samples were successfully amplified using long-range PCR. Among these, 98.2% were
successfully reported by NGS, with an accuracy rate of 99.84% in an independent blind
Quality Control audit performed by the NDMP. In this study, NGS-HLA typing identified 23
null alleles (0.023%), 92 rare alleles (0.091%) and 42 exon novelties (0.042%).
Conclusion
Long-range, unambiguous HLA genotyping is achievable on clinical buccal swab-extracted
DNA. Importantly, full-length gene sequencing and the ability to curate full sequence data
will permit future interrogation of the impact of introns, expanded exons, and other gene
regulatory sequences on clinical outcomes in transplantation.
Introduction
The HLA region contains the most highly polymorphic genes in the human genome. To date,
over 10,574 distinct HLA class I alleles and 3,658 class II alleles have been recognized (IMGT/
HLA database, December 2015). Although a high degree of HLA polymorphism is important
to combat pathogens, it creates a significant barrier for HSCT [1,2] and solid organ transplan-
tation between unrelated individuals [3]. In addition, specificHLA alleles are associated with
development of autoimmunity and drug hypersensitivity [4]. Therefore, HLA genotyping is
used for HLAmatching of donor–recipient pairs in HSCT, identification of humoral responses
to donor antigens in solid organ transplantation, and personalized risk assessment of HLA-
associated autoimmune diseases and adverse drug reactions.
Over the past two decades,molecularHLA typing techniques have replaced serological
methods in clinical applications to provide more precise results. Three basic methods used in
conjunction with polymerase chain reaction (PCR) employ sequence-specificoligonucleotide
probes (SSOP), sequence-specificprimers (SSP), and sequencing-based typing (SBT) [5]. How-
ever, due to their low throughput and high cost, HLA typing using these methods principally
focuse on the antigen recognition site (ARS) of HLA genes (exon 2 and 3 for HLA class I and
exon 2 for class II) where the polymorphisms are predominantly found. RestrictingHLA typ-
ing to the ARS regions hampers the assignment of high-resolution genotypes and the identifi-
cation of null alleles with variants outside of the ARS. In addition, these conventional DNA
typing methods cannot distinguish between polymorphisms residing on the same chromosome
(cis) or different chromosomes (trans), thereby creating ambiguities that are difficult, time-
consuming and expensive to resolve [6]. Recently, a number of groups have successfully lever-
aged the throughput power of massive parallel sequencing, or NGS, to deliver unambiguous
HLA typing with relatively low cost [7–15]. Significant cost reduction is expectedwith simpli-
fied protocols, improved efficiencyof reagents/chemistries, and introduction of automated
platforms.
Since the initial feasibility study published in 2009 [16,17], several other groups have devel-
oped variations in the technique and strategy of HLA genotyping by NGS; however, most of
the studies are small in sample size [9,10,12–15,18,19], and the majority were performed using
blood samples. Here we describe the development and validation of a high-throughput HLA
Next-Generation Sequencing for HLA Typing
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typing workflow using buccal swab samples in our laboratory [11]. Using this method, we suc-
cessfully converted our National Marrow Donor Program (NMDP) registry typing contract
from traditional typing using the SSO/SBTmethodology to high-resolutionNGS typing start-
ing October 2014. The NMDP is the largest HSCT donor registry in the world with more than
11 million potential donors listed. Currently, buccal swabs are utilized as a noninvasive sample
collectionmethod for NMDP registry donors. However, buccal swab DNA has several limita-
tions that pose unique challenges for typing by NGS. First, buccal-derivedDNA yield is much
lower than that obtained from peripheral blood. It has been reported that epithelial cells recov-
ered from the mouth are usually superficial and about 25% of these cells are in the process of
apoptosis [20]. Second, DNA isolated from cheek cells may contain exogenous DNA from bac-
teria that interfere with the downstream PCR efficiency and data analysis [20]. Finally, buccal
DNA is prone to nucleic acid degradation, which may limit the success of long-range PCR. In
this manuscript, we report the development of an automated, NGS-based,HLA typing method
for registry typing at HLA-A, -B, -C, -DRB1, -DQB1 on buccal specimens which can overcome
these limitations to provide high quality, high-resolutionHLA typing.
Materials and Methods
Buccal swab (g)DNA samples
Sterile cotton tipped applicator swabs kits (LabCorp, USA) were used to collect buccal epithe-
lial cells by brushing the cotton tip against the inside of mouth cheek for 10 seconds. After
receiving buccal swab samples from the NMDP, DNA was isolated using QIAamp 96 DNA
Swab BioRobot Kit (Qiagen, Germany) on the Qiagen BioRobot Universal System (Qiagen,
Germany) before downstream application. Research approval for performingNGS sequencing
on these samples was granted by the UCLA Institutional ReviewBoard (IRB#14–000516).
PCR amplification, pooling, clean-up
Multiplex long-range PCR primers (One Lambda, Canoga Park, CA) were designed to co-
amplify HLA-A, -B, -C from promoter to 3’-UTR. For HLA class II genes, long-range PCR
primers amplified HLA-DRB1 and DQB1 beginning at exon 2 through part of exon 4 (One
Lambda, Canoga Park, CA) in separate reactions (Fig 1). In brief, each PCR reaction consisted
of: 5μL of buccal swab gDNA, 4μL polymerase buffer, 1.6μL dNTPmixture, 5μL primer mix,
and 0.8μL PrimeSTAR GXLDNA polymerase (TaKaRa Bio Inc., Japan), making a final volume
of 20μL. GeneAmp PCR system 9700 (Life Technologies, Carlsbad, CA) thermal cycler condi-
tions for class I genes were: 94°C for 2 min, followed by 35 cycles of (98°C for 10 s, 70°C for 3
min). For class II, the optimized conditions were: 94°C for 2 min, followed by 35 cycles of
(98°C for 10 s, 69°C for 3 min). PCR products were confirmed on 0.8% agarose gel (Sigma–
Aldrich, St. Louis, MO), and then mixed with Agencourt AMPure XP beads (BeckmanCoulter,
Brea, CA) in 0.6× PCR reaction volume to undergo purification using Biomek NX (Beckman
coulter, Brea, CA). Qubit fluorometer 2.0 (Life technologies, Grand Island, NY) was used to
quantitate and normalize amplicon concentrations, accounting for the different amplicon frag-
ment lengths; this was followed by equimolar pooling of class I and class II PCR products.
Library construction
Amplicons of HLA class I and class II genes were sheared using Covaris M220 (Covaris,
Woburn, MA). We aimed to obtain an insert size of 500–600 bp to maximize the phasing of
linked polymorphisms. Amplicon fragments underwent further purification with Agencourt
AMPure XP beads in 1.6× reaction volume. Sheared amplicons then underwent library
Next-Generation Sequencing for HLA Typing
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preparation using the TruSeq Nano DNA sample preparation kit (Illumina, San Diego, CA).
Library constructionwas automated on the Biomek FX (Beckman coulter, Brea, CA). After
end-repair, library templates proceeded to double size selection: large fragments were removed
using diluted AMPure XP beads in 1.6× reaction volume; small fragments were removed by
mixing 30μL of undiluted AMPure XP beads with 250μL of sample supernatant containing the
DNA of interest. Following adenylation, Illumina adapter indices were ligated to the purified
fragments, such that pooled PCR products from each clinical sample were labeled with a
unique adaptor index. From each library sample, 25 μLwas then mixed with 5μL PCR Primer
Cocktail and 20μL Enhanced PCRMix to carry out target library enrichment with a limited-
cycle PCR: 95°C for 3 min, followed by 8 cycles of (98°C for 20 s, 60°C for 15 s, 72°C for 30 s),
and 72°C for 5 min. Enriched libraries were then purifiedwith AMPure XP beads in a 1:1 ratio.
Library normalization, pooling, and sequencing on MiSeq
Sequence-ready libraries were validated and quantitated on the High Sensitivity D1000 Screen-
Tape (Agilent Technologies, Santa Clara, CA) to allow for library normalization and equimolar
pooling of all study samples on the Biomek FX (Beckman coulter, Brea, CA). Pooled libraries
were diluted and loaded at 12 pM on a MiSeq flow cell, with 5% phiX spiked in. Paired end
sequencing runs were performed usingMiSeq Reagent Kit v2, 500 cycles (Illumina, San Diego,
CA).
Fig 1. HLA typing strategy. The primer design captures full-length HLA class I genes (HLA-A, -B, -C) and exons 2–4 of DRB1 and DQB1 genes. There are
two multiplex primer sets: Class I primer mix includes HLA-A, -B, -C, and Class II primer mix includes DRB1 and DQB1.
doi:10.1371/journal.pone.0165810.g001
Next-Generation Sequencing for HLA Typing
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HLA sequence data analysis and genotype calling
Raw sequence outputs were imported as unpacked and gzipped FASTQ files into Omixon
Twin V1.0.7 software (Omixon, Budapest, HU) for read alignment and genotype calling (using
IMGT/HLADatabase 3.19.0 as reference). A read length of 15 bp or greater was the prerequi-
site for read alignment. The default minimum coverage threshold used to assign genotypes was
set at 100.
Luminex LABType SSO validation
SSO validation was performed using the LABType SSO kit (One Lambda, Inc., USA). 2μL of
buccal swab g(DNA) was used for amplification. Next, 5 μL of amplified DNA was denatured
at room temperature for 10 min. DNA was hybridized to oligonucleotide probes immobilized
on Luminex beads at 60°C for 15 min. After labeling, the tray was loaded on a Luminex 100/
200 IS Flow Analyzer (Luminex Corporation,USA) for data generation and analysis using the
HLA Fusion software (One Lambda, Inc., USA).
SBT validation of exon novelty
Variants identified in exon 1–4 of HLA-A, -B, exon 1–7 of HLA-C, and exon 2–3 of
HLA-DRB1, -DQB1 were verified using the SBT resolver (ConexioGenomics Ltd, Australia).
Mutations residing in other locations were validated using in-house SBT primers. 5μL of buccal
swab g(DNA) was used for long-range PCR followed by purification with ExoSAP (Affymetrix,
CA). The BigDye Terminator v1.1 Cycle Sequencing (Life technologies,NY) reaction consisted
of: Ready Reaction Premix 4μL, BigDye Sequencing Buffer 2μL, Primer (3.2 pmol), purified
template 2μL, and H2O to make-up a volume of 20μL followed by incubation at 96°C for 1min
and 25 cycles of (96°C for 20 s, 50°C for 30s, 60°C for 2min). Sequence products were purified
using ethanol precipitation and eluted with 15μL of Hi-Di™ Formamide (Life Technologies,
NY) before loading on a 3730xl DNA analyzer (Applied BiosystemsUSA). Data was analyzed
using UType.
Results
UCLA high-throughput NGS workflow and long range PCR
Our laboratory developed an automated, high-throughput HLA typing workflow by integrat-
ing the Beckman FX robotic liquid handler with the IlluminaMiSeq. This method allows for
high volume typing at 5 HLA loci (HLA-A, B, C, DRB1 and DQB1) with a rapid 5-day turn-
around-time (TAT) to genotype reporting (Fig 2). This strategy was able to resolve all third-
field ambiguities for HLA class I and all second-field ambiguities for class II alleles. Since
DRB1 and DQB1 genes were only partially amplified, ambiguities involving DRB104:07/
DRB104:92 (exon 4), DRB109:01/DRB109:21 (exon 4), and DRB112:01/DRB112:10 (exon
1) were still encountered.
From October 2014 to October 2015, 10,063 buccal swab samples were successfully typed
using this strategy. Among the samples tested during development, the average concentration
of DNA isolated from buccal swabs was 3.96 ± 3.74 ng/μL in 100μL volume (n = 96) (Fig 3).
While this yield was approximately 6-fold lower than DNA isolated from whole blood control
specimens (n = 56, 23.99 ± 9.24 ng/μL), the total DNA quantity (range: 1.91–75.5 ng) was
sufficient to generate enough amplicons for downstream application after 35 cycles of PCR.
Additionally, despite known challenges associated with buccal-derivedDNA, robust PCR
amplification was achieved on 9,842 NMDP samples (97.8%) during the study period (Fig 4),
Next-Generation Sequencing for HLA Typing
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with 221 samples (2.2%) experiencingPCR failure due to low quality and/or quantity of buccal
swab DNA.
NGS typing results
Overall,> 82% of IlluminaMiSeq paired-end sequencing base calls exceeded a quality score of
30 (Q30), indicating that the probability of an incorrect base call was less than 1 in 1000. The
average coverage depth was greater than 500 bp across all loci and uniform coverage was gener-
ally observed throughout the entire region (Fig 5). A slight coverage decrease was found in
intron 3 of all DRB1 alleles due to the (GT)x(GA)y motif, which was previously reported [11].
Following sequencing, all reads were analyzed using Omixon Twin (V.1.0.7) which combines
Fig 2. High-throughput NGS workflow. High-throughput NGS workflow begins with multiplex long range PCR of A, B, C and DRB1, DQB1. After PCR,
amplicons are purified and pooled in equimolar concentrations. Sheared amplicons then undergo library preparation by using the Illumina TruSeq Nano
Kit. To maximize throughput, each clinical sample is labeled with unique dual indices. 2×250 bp paired-end sequence data from the Illumina MiSeq are
exported and analyzed using Omixon Twin1.0.7, with 3.19.0 IMGT/HLA database serving as the reference.
doi:10.1371/journal.pone.0165810.g002
Next-Generation Sequencing for HLA Typing
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two independent analysis algorithms (statistical alignment and de novo assembly) for robust
variant calling. In addition, several embedded quality metrics (read length, read quality, noise
ratio, consensus coverage, imbalance ratio, PCR crossover artifact detection, crossmapping
reads among different loci and phasing) improved the accuracy and the confidence of allele
calling. Among the 9,842 samples (98425 loci2 diploid = 98,420 alleles) that were successfully
amplified, 96,686 alleles (96,686/98,420 = 98.2%) were successfully reported by NGS (Table 1).
When all the quality metrics were met, concordant allele calling was assigned on 95,342 alleles
(95,342/96,686 = 98.6%) by both de novo assembly and statistical alignment algorithms. Over-
all, 2,380 alleles (2,380/96,686 = 2.5%) were flaggedwith QCwarning by Omixon Twin that
required furthermanual analysis- 1,344 alleles were reported by NGS after careful manual eval-
uation (e.g. to ensure complete and sufficient coverage); typing for the remaining 1,036 alleles
could not be assigned. Since low DNA quantity and poor sample integrity are known to
Fig 3. Comparison of DNA concentration in buccal swab and blood samples. The average concentration of buccal-isolated DNA
was 3.96 ± 3.74 ng/μL in 100μL volume, which was significantly lower than DNA derived from blood samples (23.99 ± 9.24 ng/μL).
doi:10.1371/journal.pone.0165810.g003
Next-Generation Sequencing for HLA Typing
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promote allele dropouts, all homozygous alleles as identified by NGS were confirmed by SSO
typing. Parallel SSO testing identified 349 allele dropouts (0.35%) among all buccal swap sam-
ples sequenced (S1 Table). Allele dropouts were detected across all five loci (A = 111, B = 74,
C = 63, DRB1 = 69, and DQB1 = 32). The most common allele dropout was A02:01:01 which
occurred in 26 samples. However, since A02:01:01 is a high frequency allele, the dropout rate
was only 0.57% (26/4571). On the contrary, B38:01:01 dropout was found in 9 out of 378
alleles, yielding a higher relative dropout rate of 2.38% compared to the A02:01:01 allele- this
suggests a possible primer design issue which requires further optimization. Interestingly, no
allele dropouts were detected in 122 blood-based specimens validated in our lab using the same
amplification strategy; therefore, primer-independent issues such as DNA quantity/quality
were likely significant factors predisposing to allele dropouts in buccal-derived specimens.
NGS typing results were exported fromOmixon Twin and reported to the NMDP using
HistoimmunogeneticsMarkup Language (HML) [21]. HML is an electronicmessaging format
that was developed based on Minimum Information for Reporting Immunogenomic NGS
Genotyping (MIRING) reporting guidelines (miring.immunogenomics.org). A MIRINGmes-
sage includes five categories of structured information (message annotation, reference context,
full genotype, consensus sequence, novel polymorphism) and three pieces of accessory infor-
mation (NGS platform documentation, read processing documentation and primary data)
[22]. Using this format, HLA genotyping results can be readily updated in accordance with ref-
erence and nomenclature databases. During the period of this study, an overall NGS-HLA typ-
ing accuracy rate of 99.84% was achieved across all five loci (A, -B, -C, -DRB1, and -DQB1)
based on independent testing of 264 blind Quality Control samples by the NMDP (Table 1).
Fig 4. Long-range PCR products and gel electrophoresis. a) Gel electrophoresis of Class I (HLA-A, B, C) using a multiplex primer set. b) Gel
electrophoresis of Class II (DQB1 and DRB1) using a multiplex primer set. White box denotes PCR failure. P and N refer to positive control and negative
control, respectively.
doi:10.1371/journal.pone.0165810.g004
Next-Generation Sequencing for HLA Typing
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Null, novel and rare alleles detected by NGS in 10,063 buccal swab
samples
UnrecognizedHLA null alleles or novel alleles may affect the outcome of HSCT [23]. A total of
23 null alleles were identified resulting in a prevalence of 0.023% in this cohort (Table 2). The
most common null allele detectedwas C04:09N. C04:09N differs from C04:01:01 in exon 7
where C04:09N carries a frameshift base pair deletion in codon 341 that leads to a loss of stop
codon in exon 8. All C04:09N alleles detected in this dataset were in linkage with B44:03.
The majority of novel polymorphisms detected in this study were found within introns. Due to
the paucity of complete intron consensus sequences and a lack of reagents to confirm intron muta-
tions, we elected to prioritize verification of exon novelties, which are known to be the most clini-
cally relevant, and at intron-exon junctions that are predicted to create alternative splicing. During
the study period, 42 exon novelties were detected by NGS and confirmedby SBT (Table 3). New
Fig 5. Coverage data taken from a representative sample. The sample was aligned using GenDX Version1.9.0. Blue box, UTR; yellow box, exon. black
line, intron. Red box shows the low coverage region in intron 3 of all DRB1 alleles. Uniform coverage was achieved in most loci with the exception of
coverage bias found in intron 3 of DRB1 alleles due to the (GT)x(GA)y motif.
doi:10.1371/journal.pone.0165810.g005
Table 1. NGS typing results.
9842 samples PCR Amplified(n = 98,420 alleles) HLA-A HLA-B HLA-C HLA-DRB1 HLA-DQB1 Total
Concordant allelic calling by Omixon Twin 18,622 18,808 19,328 19,110 19,474 95,342
Omixon Twin QC warning Reported after manual analysis 518 452 118 174 82 1,344
QC failure 316 364 134 118 104 1,036
Allele Dropout 111 74 63 69 32 349
Total % reported by NGS 97.3% 97.4% 98.7% 98.7% 99.1% 98.2%
Number of NMDP blind QC error(n = 1,302 loci) 0 0 0 2 0 0.16%
doi:10.1371/journal.pone.0165810.t001
Next-Generation Sequencing for HLA Typing
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Table 2. Null allele detection by using NGS in 10,063 buccal swab samples.
HLA-
allele
Mutation Numbers
detected
Frequency
(%)
A*01:16N Insertion in Exon 3, 532-533insG, in codon 154, causes frameshift and premature stop at codon 196 1 0.005%
A*24:09N Point mutation at Exon 4, 742-744CAG>TAG, causes Q224X, a premature stop at codon 224 1 0.005%
A*24:11N Insertion at Exon 4, 627-628insC, in codon 186, causes frameshift and premature stop at codon 196 1 0.005%
C*04:09N Deletion in Exon 7, 1095delA, in codon 341, causes frameshift and loss of stop codon in exon 8, resulting in
the peptide containing an additional 32 amino acids
19 0.094%
C*05:07N Deletion in Exon 3, 352-353delAC, in codon 94, causes frameshift and premature stop at codon 113 1 0.005%
doi:10.1371/journal.pone.0165810.t002
Table 3. Exon novelty detection by Omixon Twin 1.0.7 through 10,063 buccal swab samples.
Alleles Location Amino Acid change Number Detected GenBank Accession#
A*01:01:01NEW Exon 4, 237 (GGG>AGG) Non-synonymous 1 KX622665
A*02:01:01NEW Exon 1, -21 (ATG>GTG) Non-synonymous 3 KX622669KX622670KX622671
A*11:01:01NEW Exon 3, 131 (CGC>TGC) Non-synonymous 1 KX622667
A*11:01:01NEW Exon 3, 144 (AAG>GAG) Non-synonymous 1 KX622668
A*24:02:01NEW Exon 1, -22 (GTC>GTT) Synonymous 5 KX622659KX622660KX622661KX622662KX622663
A*24:02:01NEW Exon 1, -19 (CCC>CTC) Non-synonymous 1 KX622672
A*24:02:01NEW Exon 2, 76 (GAG>GCG) Non-synonymous 1 KX622666
A*24:02:01NEW Exon 6, 316 (AAA>GAA) Non-synonymous 1 KX622675
A*26:01:01NEW Exon 1, -7 (GCC>GCT) Synonymous 1 KX622673
A*30:04:01NEW Exon 1, -9 (GCC>ACC) Non-synonymous 1 KX622676
A*33:01:01NEW Exon 4, 266 (CTC>CTG) Synonymous 1 KX622664
A*68:01:02NEW Exon 6, 315 (AGA>GGA) Non-synonymous 1 KX622674
B*07:02:01NEW Exon 4, 189 (GTG>ATG) Non-synonymous 1 KX622688
B*40:02:01NEW Exon 3, 127 (AAC>AAG) Non-synonymous 1 KX622685
B*44:02:01NEW Exon 2, 43 (CCG>CGG) Non-synonymous 1 KX622686
B*44:34:02NEW Exon 2, 24 (GCA>TCA) Non-synonymous 1 KX622684
B*55:01:01NEW Exon 2, 43 (CCG>TCG) Non-synonymous 1 KX622687
C*01:02:01NEW Exon 1, -17 (ACC>AAC) Non-synonymous 1 KX622683
C*03:04:01NEW Exon 2, 29 (GAC>GAT) Synonymous 1 KX622677
C*03:05NEW Exon 5, 301 (GGA>GAA) Non-synonymous 1 KX622681
C*04:01:01NEW Exon 2, 78 (CTG>CTA) Synonymous 1 KX622679
C*04:01:01NEW Exon 6, 321 (TGC>TGT) Synonymous 1 KX622682
C*07:02:01NEW Exon 3, 163 (ACG>ATG) Non-synonymous 1 KX622678
C*16:01:01NEW Exon 4, 229 (GAG>AAG) Non-synonymous 1 KX622680
DRB1*03:01:01NEW Exon 3, 149 (CAC>CAG) Non-synonymous 1 KX622658
DRB1*03:01:01NEW Exon 3, 133 (CGG>CAG) Non-synonymous 1 KX622653
DRB1*04:03:01NEW Exon 2, 43 (GAC>GAT) Synonymous 1 KX622654
DRB1*07:01:01NEW Exon 3, 134 (AAC>AAT) Synonymous 1 KX622652
DRB1*10:01:01NEW Exon 3, 135 (GGC>AGC) Non-synonymous 1 KX622656
DRB1*13:01:03NEW Exon 2, 86 (GTG>GGT) Non-synonymous 1 KX622655
DRB1*15:01:01NEW Exon 3, 134 (AAC>AAT) Synonymous 1 KX622657
DQB1*02:02:01NEW Exon 3, 118 (TCG>TCA) Synonymous 1 KX622650
DQB1*03:01:01NEW Exon 3, 174 (CAC>CAA) Non-synonymous 1 KX622647
DQB1*03:01:01NEW Exon 2, 75 (TTG>TTT) Non-synonymous 1 KX622648
DQB1*05:01:01NEW Exon 3, 130 (CGG>CAG) Non-synonymous 1 KX622649
DQB1*05:02:01NEW Exon 2, 58 (GCC>ACC) Non-synonymous 1 KX622651
doi:10.1371/journal.pone.0165810.t003
Next-Generation Sequencing for HLA Typing
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alleles were identified in 0.09% of HLA-A, 0.02% of -B, and 0.03% of -C alleles (Fig 6A and 6B).
Since our typing strategy only covered exon 2–4 of class II genes, the percentage of novel alleles
detectedwas probably underestimated. Around 67% of these novelties were non-synonymous
mutations (Table 3). They were mainly located in exon 1, 2, and 3 of HLA class I (n = 12, 10, and
14 respectively). A24:02:01NEWwas associatedwith the highest number of mutations, with six
detected in exon 1, one in exon 6, and one in exon 2. All novel alleles have been submitted to Gen-
bank and the IMGT/HLAdatabase.
We analyzed our results according to the common and well documented alleles (CWD2.0.0)
and identified 92 alleles that were not on the CWD list (Fig 6C and Table 4). Interestingly,
B15:220 was detected in 11 of the 10,063 samples with an allele frequency of 0.055%. B15:220
differs from B15:03:01 by one nucleotide in exon 1 where B15:03:01 carries a cytosine (C) and
B15:220 carries a thymine (T). The 47C->T substitution results in an amino acid change from
alanine to valine in the signal peptide at amino acid position −9. Other rare alleles included
C04:12 and DQB106:01:03, both detected 3 times in the cohort (frequency= 0.015%). These
alleles should be re-characterized as common and well defined alleles.
Discussion
To date, several groups have developed different protocols and workflows for HLA genotyping
by NGS; however, most of the published studies are small in sample size [9,10,12–15,18,19]
and the majority were performed using blood-based specimens. Here, we report our NGS-HLA
typing experience performed on buccal DNA isolated fromNMDP registry donors. Of the
10,063 samples tested over the one-year period, robust PCR amplification was accomplished in
9,842 samples (97.8%). Overall, a typing accuracy of 99.8% was achieved based on independent
testing of 265 blind QC samples embedded into the study cohort. A total of 42 exon novelties,
23 null alleles, and 92 alleles were identified in this study.
There are many advantages to using buccal swab specimens for clinical testing.While
peripheral blood is routinely used for PCR-based assays, blood sampling is invasive, time-con-
suming, and expensive. These limitations are challenging for high volume donor recruitment
typing, particularly when participants are dispersed geographically. Buccal swabs, on the other
hand, are considered a convenient alternative for collecting genetic material, as they are rela-
tively inexpensive, noninvasive and can bemailed out for self-collectionand return-mailed for
centralized testing [24,25]. In our study, DNA yield from buccal swabs was approximately six
times lower than DNA isolated from blood samples. DNA degradation can occurwhen bacte-
rial contamination digests DNA strands. Therefore, keeping buccal swabs in a cool and dry
environment can mitigate the degradation process by limiting the generation of inhibitory sub-
stances. The variation of the DNA yield is also influenced by individual collection techniques.
Samples with low DNA copy number are known to be more subject to PCR inhibitory sub-
stances. Despite these known challenges, robust long range PCR was achieved on 97.8% sam-
ples in our study, with a high percentage of specimens (98.2%) being reported successfully
downstream.
One problem associated with PCR of diploid genomic DNA is the preferential amplification
of heterozygous alleles. This manifests as allele imbalance in downstreamNGS analysis-
depending on the threshold depth used for genotype calling, the analysis software may inap-
propriately perceive the low-coverage heterozygous allele as background “noise”, leading to
assignment of homozygosity with the preferentially amplified allele [26,27]. To characterize
this phenomenon, we performed parallel SSO typing of all homozygous alleles assigned by
NGS in this study. Overall, an allele dropout rate of 0.35% was observedbased on confirmatory
typing of 6,790 homozygous alleles (A = 2,220, B = 972, C = 1,470, DRB1 = 650,
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Fig 6. Novel and rare alleles detected by NGS in 10,063 samples. Sequence data was analyzed using
Omixon HLA Twin V1.0.7 (3.19.0 IMGT/HLA database). a) Percentage of SBT-confirmed exon novelties
shown by HLA locus. b) Example of a novel allele detected by NGS and confirmed using SBT. SBT was
unable to determine the cis-trans phase of the exon novelty; in contrast, parallel sequencing by NGS clearly
established the phase and location of the novel variant in the B*40:02:01 new allele. c) Percentage of rare
alleles detected shown by HLA locus.
doi:10.1371/journal.pone.0165810.g006
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Table 4. Rare alleles detected by NGS that are not present on CWD 2.0.0 in 10,063 samples.
HLA-allele G group Numbers detected Allele Frequency (%)
A*01:23 1 0.005%
A*01:37 A*01:01:01G 2 0.010%
A*02:37 1 0.005%
A*02:66 A*02:01:01G 1 0.005%
A*02:110 1 0.005%
A*03:102 1 0.005%
A*02:194 1 0.005%
A*11:47 1 0.005%
A*11:108 A*11:01:01G 1 0.005%
A*23:18 A*23:01:01G 1 0.005%
A*24:46 1 0.005%
A*26:30 1 0.005%
A*30:24 A*30:01:01G 1 0.005%
A*30:28 1 0.005%
A*66:17 A*66:01:01G 1 0.005%
A*68:44 1 0.005%
A*01:16N 1 0.005%
A*68:67 1 0.005%
A*68:93 1 0.005%
B*07:24 2 0.010%
B*07:29 1 0.005%
B*15:146 B*15:01:01G 1 0.010%
B*18:15 1 0.005%
B*18:28 1 0.005%
B*18:34 1 0.005%
B*15:220 B*15:03:01G 11 0.055%
B*27:13 B*27:05:02G 1 0.005%
B*27:25 1 0.005%
B*49:16 1 0.005%
B*58:11 B*58:01:01G 1 0.005%
B*40:126 1 0.005%
B*40:80 1 0.005%
B*44:102 1 0.005%
C*02:15 1 0.005%
C*02:21 1 0.005%
C*02:56 1 0.005%
C*03:21 1 0.005%
C*03:87 1 0.005%
C*04:12 3 0.015%
C*04:40 1 0.005%
C*04:46 1 0.005%
C*03:129 2 0.010%
C*05:37 C*05:01:01G 1 0.005%
C*06:10 1 0.005%
C*07:23 1 0.005%
C*07:74 C*07:02:01G 1 0.005%
C*07:85 1 0.005%
(Continued )
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DQB1 = 1,478). Preferential amplification may not account for all of the allele dropouts identi-
fied in this cohort. It is well known that PCR bias is subject to variations in DNA quantity or
quality, presence of PCR inhibitors, variations in pipetting volumes of reagents, imprecisions
in thermocycler temperatures and human errors. This type of bias is usually random and not
reproducible. Repeat testing of the sample may resolve the problem. Alternatively, nonrandom
amplification failures can result from extreme GC content, and preferential polymerase recog-
nition sites [28]. Additionally, allele dropout can be caused by sequence specific variations; in
this case, amplification failures occur when a given primer cannot stably hybridize to its spe-
cific complementary sequence binding site, or when novel mutations are found in the primer
binding site. This type of dropout requires redesign of primers or alternatively using two differ-
ent set of primers to capture the same allele.
Currently, only 3.21% of HLA-A (102 alleles), 4.60% of HLA-B (182 alleles), 7.71% of
HLA-C (211 alleles) and 1.42% of HLA-DRB1 (25 alleles) have complete nucleotide sequences
from 5’-UTR to 3’-UTR [29]. The typing strategy describedhere utilizes long-range PCR to
amplify full-length sequences of class I genes (HLA-A, B, C), and uninterrupted sequences
from exon 2 to beginning of exon 4 of class II (HLA-DRB1 and DQB1), thereby providing
valuable intron information involving previously unmapped regions. Intron sequences consti-
tute approximately 30% of the human genome [30]; however, the function of introns is not
completely understood. Recent NGS studies have shown that noncoding RNAs (ncRNAs),
including miRNA, siRNA, long noncoding RNAs (lncRNAs) and small nucleolar RNAs
Table 4. (Continued)
HLA-allele G group Numbers detected Allele Frequency (%)
C*07:179 1 0.005%
C*12:06 1 0.005%
C*12:07 1 0.005%
C*12:24 1 0.005%
C*15:24 1 0.005%
C*16:14 1 0.005%
DRB1*03:19 1 0.005%
DRB1*03:49 1 0.005%
DQB1*02:07 1 0.005%
DQB1*02:10 DQB1*02:01:01G 1 0.005%
DQB1*02:26 2 0.010%
DQB1*02:28 1 0.005%
DQB1*03:03:04 DQB1*03:03:02G 1 0.005%
DQB1*03:24 DQB1*03:01:01G 2 0.010%
DQB1*03:25 1 0.005%
DQB1*03:55 1 0.005%
DQB1*03:58 1 0.005%
DQB1*05:02:07 DQB1*05:02:01G 1 0.005%
DQB1*06:01:03 DQB1*06:01:01G 3 0.015%
DQB1*06:01:08 1 0.005%
DQB1*06:02:02 1 0.005%
DQB1*06:07:01 1 0.005%
DQB1*06:14:01 1 0.005%
DQB1*06:16 2 0.010%
DQB1*06:50 1 0.005%
doi:10.1371/journal.pone.0165810.t004
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(snoRNAs) found in intron regions of the human genomemay play an important role in regu-
lating gene expression [31,32]. The role of intron sequences in HLA expression and their
importance in HSCT have recently been demonstrated in HLA-C and DP. HLA-C is expressed
at a level approximately 10-fold lower than HLA-A and B antigens [33]. The mechanism
underlying this varied expression was unknown until recently when Kulkarni and colleagues
demonstrated differential regulation of HLA-C expression through miRNA. miRNA is known
to bind to specific sites in the 3’ UTR, resulting in post-transcriptional repression, cleavage or
destabilization [34]. Kulkarni and colleagues showed that a single polymorphism (SNP) in the
3’ UTR of HLA-C affects binding of the has-miR-148 miRNA to its target site, resulting in a
relatively low HLA-C surface expression; in contrast, alleles without has-miR-148 binding
escape post-transcriptional regulations and have high HLA-C expression [35]. In HSCT,
increased expression of the recipient’s mismatched HLA-C is associated with an increased risk
of grade III and grade IV graft-versus-host disease (GVHD), non-relapse mortality and overall
mortality [36]. In addition, a SNP in the 3’ UTR of HLA-DP has been reported to alter
HLA-DP expression [37]. Position rs9277534A is associated with low DP expression while
rs9277534G is associated with high expression. In HSCT, the risk of acute GVHDwas higher
for recipients with rs9277534G-linkedHLA-DPB1 mismatches than for recipients with
rs9277534A-linked HLA-DPB1 [37]. Intronic mutations can also result in null allele expres-
sion. Although we did not identify intronic null mutations in our dataset, there are seven null
alleles in the IMGT/HLA database (v.3.23.0) that lead to null protein expression due to alter-
ations in mRNA splicing. Since the serologicalmethod is no longer commonly used for HLA
typing, aberrant HLA expression due to unrecognizedmutations cannot be fully appreciated
until complete gene sequences are routinely interrogated and curated.
Herein, we report our experience of high-throughput, high-resolutionNGS-HLA typing for
NMDP donors with high accuracy. The combination of automation and robust data analysis
software makes NGS typing a cost effective solution for sequencing registry donors. Further,
the ability to deliver unambiguous typing holds great promise to facilitate timely donor identi-
fication for HSCT recipients. Since>90% of HLA class I and class II genes do not have com-
plete sequences [29], our results made it possible to fill in gaps in the existing HLA database.
By analyzing polymorphisms in the entire region of HLA genes, the importance of polymor-
phisms outside ARS in introns, promoters, enhancers, and UTRs can be further revealed in
transplantation, autoimmunity, diseases association, and pharmacogenomics.
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